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Abstract
Mycoplasma hyopneumoniae infections are responsible for significant economic losses in the
swine industry. Commercially available vaccines are not able to inhibit the colonisation of the
respiratory tract by M. hyopneumoniae absolutely, therefore vaccination can be completed
with antibiotic treatment to moderate clinical signs and improve performances of the animals.
Antibiotic susceptibility testing of M. hyopneumoniae is time-consuming and complicated;
therefore, it is not accomplished routinely. The aim of this study was to determine the in vitro
susceptibility to 15 different antibiotics of M. hyopneumoniae isolates originating from Hungar-
ian slaughterhouses and to examine single-nucleotide polymorphisms (SNPs) in genes
affecting susceptibility to antimicrobials. Minimum inhibitory concentration (MIC) values of the
examined antibiotics against 44 M. hyopneumoniae strains were determined by microbroth
dilution method. While all of the tested antibiotics were effective against the majority of the
studied strains, high MIC values of fluoroquinolones (enrofloxacin 2.5 μg/ml; marbofloxacin
5 μg/ml) were observed against one strain (MycSu17) and extremely high MIC values of
macrolides and lincomycin (tilmicosin, tulathromycin and lincomycin >64 μg/ml; gamithromy-
cin 64 μg/ml; tylosin 32 μg/ml and tylvalosin 2 μg/ml) were determined against another, outlier
strain (MycSu18). Amino acid changes in the genes gyrA (Gly81Ala; Ala83Val; Glu87Gly,
according to Escherichia coli numbering) and parC (Ser80Phe/Tyr; Asp84Asn) correlated
with decreased antibiotic susceptibility to fluoroquinolones and a SNP in the nucleotide
sequence of the 23S rRNA (A2059G) was found to be associated with increased MIC values
of macrolides. The correlation was more remarkable when final MIC values were evaluated.
This study presented the antibiotic susceptibility profiles of M. hyopneumoniae strains circu-
lating in the Central European region, demonstrating the high in vitro efficacy of the tested
agents. The observed high MIC values correlated with the SNPs in the examined regions and
support the relevance of susceptibility testing and directed antibiotic therapy.
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Introduction
Mycoplasma hyopneumoniae is a member of the class Mollicutes [1] and the causative agent of
porcine enzootic pneumonia [2]. M. hyopneumoniae infection affects especially growing pigs,
causing significant economic losses in the swine industry worldwide, by chronic cough,
growth retardation and predisposing animals to secondary infections [3–6]. Improvement of
the management system and the environmental conditions of pig farms are essential parts of
the control strategies just like vaccination and antibiotic treatment [4,7,8]. As vaccination
alone is not always effective enough to prevent colonisation of the respiratory tract [9], antibi-
otic treatment might be necessary [4].
Mycoplasmas are resistant to antimicrobials that interfere with folic acid metabolism and
cell wall synthesis, like sulphonamides, trimetoprim and the β-lactam class of antibiotics
[5,10]. Macrolides, tetracyclines, fluoroquinolones, some aminoglycosides and aminocyclitols,
lincosamides and pleuromutilins are active antimicrobial agents against M. hyopneumoniae
[4,11]. However, studies have already drawn attention on the emergence of antibiotic resis-
tance in M. hyopneumoniae to fluoroquinolones, macrolides, lincosamides and tetracyclines
[12–14]. The decreased susceptibility may appear as a consequence of excessive medication
[13,15,16]. The basics of in vitro susceptibility testing with microbroth dilution method were
laid down almost 20 years ago [17], however, important points of standardisation are still
absent.
Genomic changes (e.g. single-nucleotide polymorphism (SNP)) related to decreased effec-
tiveness of certain antibiotics have been identified in previous publications [14,15,18,19]. Fluo-
roquinolones and macrolides are among the most frequently utilised antibiotic agents to
control M. hyopneumoniae infection in Hungary [20,21]. The targets of the fluoroquinolone
type antibiotics enrofloxacin and marbofloxacin, are topoisomerase enzymes (DNA gyrase
and topoisomerase IV), which have essential role in bacterial DNA replication [15,18]. Emerg-
ing resistance to fluoroquinolones in mycoplasmas is usually due to transitions in the quino-
lone resistance-determining regions (QRDR) in genes encoding subunits of the topoisomerase
enzymes (gyrA, gyrB, parC, parE) [19,22]. The majority of the substitutions, causing amino
acid change and therefore increased MIC values, are observed in the parC gene (e.g. Ser80Phe,
Ser80Tyr, Asp84Asn and Ala116Glu, according to Escherichia coli numbering) [15,18]. The
amino acid change Ala83Val in gyrA gene was also described to be related to decreased suscep-
tibility to enrofloxacin in M. hyopneumoniae [18]. Further amino acid substitutions in the
gyrA gene observed in other Mycoplasma species were for example Gly81Ala or Glu87Gly
[23,24]. According to the literature, 14-membered macrolides show low MIC against M. hyop-
neumoniae due to a G2057A transition in the 23S rRNA sequence [14]. In addition, adenosi-
ne!guanosine transition at nucleotide 2058 in the same region is frequently observed in
association with increased resistance to 15- and 16-membered macrolides and lincosamides
[14,25].
The aim of this study was to describe the antibiotic susceptibility profile of 44 M. hyopneu-
moniae strains isolated from Hungarian slaughterhouses in years 2015 and 2016, against 15
antimicrobial agents and to examine the genetic background of increased MIC values.
Materials and methods
Sample collection
Forty-four M. hyopneumoniae strains originating mainly from Hungary (n = 40), but also
from Slovakia (n = 3) and the Czech Republic (n = 1) were tested in this study (S1 and S2
Tables). Hungarian slaughterhouses were visited between 2015 and 2016 for sampling. Ethical
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approval and specific permission were not required for the study as all affected porcine lung
samples, used for the isolation, were collected by the authors with the consent of the owners
during routine diagnostic examinations of the carcasses in slaughterhouses. The affected lung
samples were washed into Friis broth [26], and filtered through a 0.45 μm filter. The broth was
diluted 30-fold and incubated for 4 weeks or until colour change at 37 ˚C. After the incubation
period a 10-fold serial dilution was prepared, and incubated until colour change [27]. When
colour change of the broth media occurred cultures were inoculated onto solid media and
incubated at 37 ˚C and 5% CO2 for 4–10 days, until visible colonies appeared. Mycoplasma
strains were once filter-cloned, and DNA extraction was performed from the pure cultures
using QIAamp DNA mini kit (Qiagen Inc., Hilden, Germany) according to the manufacturer’s
instructions. Species-specific PCR test was accomplished to confirm the presence of M. hyop-
neumoniae [28]. To exclude the presence of other Mycoplasma species sequence analyses and
BLAST search were carried out using the amplicons of a universal Mycoplasmatales PCR sys-
tem targeting the 16S/23S rRNA intergenic spacer region [29]. PCR products were sequenced
on ABI 3130XL genetic analyser (Applied Biosystems, Foster City, CA). Aliquots of purified
cultures were stored frozen at -70 ˚C until usage.
Antibiotic susceptibility testing
The number of colour changing units (CCU) was determined by microbroth dilution method
after four weeks of incubation [17]. Antimicrobial agents frequently used in Hungary [21]
were selected for susceptibility tests: fluoroquinolones (enrofloxacin, marbofloxacin), amino-
glycosides (gentamicin), aminocyclitols (spectinomycin), tetracyclines (oxytetracycline,
doxycycline), macrolides (tylosin, tilmicosin, tylvalosin, tulathromycin, gamithromycin),
pleuromutilins (tiamulin, valnemulin), phenicols (florfenicol) and lincosamides (lincomycin).
Tylvalosin originated from ECO Animal Health Ltd., UK (Aivlosin), tulathromycin originated
from Pfizer Inc., USA, and the rest of the products originated from VETRANAL, Sigma-
Aldrich, Germany. The antibiotics were diluted and stored according to the recommendation
of Hannan [17]. Stock solutions of 1 mg/ml were prepared in sterile distilled water, except the
fluoroquinolones, tulathromycin, gamithromycin and florfenicol. Stock solutions of 1 mg/ml
enrofloxacin and marbofloxacin were prepared in 0.1 M NaOH and stock solutions of 1 mg/
ml tulathromycin, gamithromycin and florfenicol were prepared in 96% ethanol and sterile
distilled water. Aliquots were stored at -70 ˚C until required, precipitation on thawing was
checked before usage and dilutions for each test were freshly prepared. Twofold dilutions were
made in the range 0.039–10 μg/ml for fluoroquinolones, pleuromutilins and doxycycline;
0.25–64 μg/ml for macrolides, gentamicin, spectinomycin, lincomycin and oxytetracycline;
0.125–32 μg/ml for florfenicol. Microbroth dilution test was accomplished using a 96-wells
microtiter plate, containing growth control (bacterium culture in broth media), sterility con-
trol (broth media without bacterium culture) and end point control (sterile broth media
adjusted to pH 6.8). By reason of the more pronounced colour change of the media, Myco-
plasma Experience broth medium (Mycoplasma Experience Ltd., Bletchingley, United King-
dom) was applied for determining the number of CCU of strains and the susceptibility tests.
The antibiotic susceptibility test was accomplished on 104−105 CCU/ml of the strains as rec-
ommended by Hannan [17]. All strains were tested in duplicates and all plates contained a
duplicate of the type strain (NCTC 10110) as a quality control. MIC was established as the low-
est antibiotic concentration where no colour change of the broth was observed as a conse-
quence of the absence of bacterial metabolism. Initial MIC values were recorded when colour
change of the broth media of the growth control was visible (4–14 days after inoculation)
(S1 Table), and final MIC values were registered when no further colour change was observed
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(S2 Table). MIC50 and MIC90 values were determined as the lowest concentrations that inhib-
ited the growth of 50% or 90% of the strains [17].
Sequence analysis
Genetic markers correlating with antibiotic susceptibility in M. hyopneumoniae were exam-
ined in genes gyrA, gyrB, parC, parE and 23S rRNA [14,15,18,19]. While for the amplification
of the genes gyrA and gyrB primers and heat profile were used according to Vicca et al. [18],
for the amplification of genes parC and parE, primers and heat profile were used according to
Le Carrou et al. [15], with modification of the annealing temperature to 56 ˚C. For the analysis
of the 23S rRNA sequence the PCR conditions of Stakenborg et al. [14] were used with some
modification of the annealing temperature to 56 ˚C and the following forward (5’ GAT GAG
TAT TCT AAG GTG AGC GAG 3’) and reverse (5’ CAG TCA AAC TAC CCA CCA CG
3’) primers. PCR products were sequenced on ABI 3130XL genetic analyser (Applied Biosys-
tems, Foster City, CA) and sequence analysis was performed by using Geneious software
10.2.3 (Biomatters Ltd.) [30]. The validity of SNPs was confirmed by manual examination of
the assembled sequences. Numbering of nucleotide and amino acid positions is based on
genes and proteins of Escherichia coli strain K-12 substrain MG1655 (GenBank accession
number CP014225). Susceptibility profiles and correlating genetic markers were evaluated in
relation with previously determined genotypes of the examined strains also [31].
Results
Antibiotic susceptibility profiles
The initial MIC values are evaluated and discussed throughout the study [17], however, differ-
ences were registered between initial and final MIC values in certain cases (S1 and S2 Tables).
MIC values of the studied antimicrobial agents against the type strain (NCTC 10110) were
consistent throughout the study (Table 1), and these results were mostly in accordance with
previously defined values gained by microbroth dilution method (enrofloxacin 0.015–0.2 μg/
ml, marbofloxacin 0.031 μg/ml, oxytetracycline 0.12–1 μg/ml, gentamicin 0.25–5 μg/ml, tylo-
sin�0.015–0.06 μg/ml, tylvalosin 0.06 μg/ml, lincomycin 0.05–0.125 μg/ml, tiamulin 0.008–
0.125 μg/ml, valnemulin�0.001–0.008 μg/ml) [11–13,32–34]. However, minor differences
(two-fold increase or decrease) were observed in the MIC values against the type strain com-
pared to earlier data in case of doxycycline (0.06–0.5 μg/ml), spectinomycin (0.5 μg/ml), tilmi-
cosin (0.25–1 μg/ml) and florfenicol (0.25–0.5 μg/ml) [13,32–34]. Moreover, the MIC value of
tulathromycin was noticeably higher (103 difference between MIC values) than that reported
in the literature (�0.001–0.002 μg/ml) [34]. Previously published MIC values for gamithromy-
cin were not available at the time of the present study. The MIC ranges, the MIC50 and MIC90
values of each antibiotic against the examined strains, are recorded in Table 1.
As official breakpoints of antibiotics against M. hyopneumoniae are not standardized, MIC
values were compared to previously published, unofficial breakpoints [11] in the present
study. No correlation was found between antibiotic susceptibility profiles and earlier assigned
genotypes of the examined strains [31].
The distribution of the MIC values of fluoroquinolones (enrofloxacin and marbofloxacin)
showed one main peak coinciding with MIC50 value at the lowest antibiotic concentration
(�0.039 μg/ml), while the other values represented equipartition with the highest MIC values
(2.5 μg/ml and 5 μg/ml, respectively) (Fig 1A and 1B). One strain (MycSu17) exceeded the
unofficial breakpoint [11], with the MIC value of 2.5 μg/ml of enrofloxacin. All of the exam-
ined tetracyclines had low MIC values with MIC50 and MIC90 values of�0.25 μg/ml and 2 μg/
ml of oxytetracycline; and 0.078 μg/ml and 0.312 μg/ml of doxycycline (Fig 1C and 1D). The
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lowest examined concentration of gentamicin (�0.25 μg/ml) was effective against most of the
studied strains (Fig 1E). MIC50 and MIC90 values of spectinomycin were 2 μg/ml, with MIC
4 μg/ml being the highest detected value (Fig 1F). Five macrolides were tested (Fig 1G–1K),
out of which tilmicosin showed a Gaussian distribution with 2 μg/ml and 4 μg/ml MIC50 and
MIC90 values, respectively. One main peak at the lowest antibiotic concentration (�0.25 μg/
ml) was observed in the MIC values of tylosin and tylvalosin against the examined strains.
MIC50 values of gamithromycin and tulathromycin were 0.5 μg/ml, while MIC90 values were
2 μg/ml and 1 μg/ml, respectively. Both MIC50 and MIC90 values of lincomycin coincided with
the lowest examined antibiotic concentration (�0.25 μg/ml) (Fig 1L). For all macrolides and
for lincomycin high MIC values (>64 μg/ml of tilmicosin and tulathromycin; 64 μg/ml of
gamithromycin; 32 μg/ml of tylosin; 2 μg/ml of tylvalosin; and>64 μg/ml of lincomycin) were
detected against an outlier strain (MycSu18). Both studied pleuromutilins had low MIC values
(Fig 1M and 1N). The MIC50 and MIC90 values of valnemulin were�0.039 μg/ml, while that
of tiamulin�0.039 μg/ml and 0.078 μg/ml. MIC50 and MIC90 values of florfenicol were 1 μg/
ml and 2 μg/ml (Fig 1O).
Single-nucleotide polymorphisms correlating with decreased antibiotic
susceptibility
High MIC values of fluoroquinolones, macrolides and lincosamides, exceeding the unofficial
breakpoints [11] were found in some cases (e.g. MycSu17-18). Both synonymous and non-
Table 1. MIC values against the type strain and summary of MIC ranges, MIC50 and MIC90 values (μg/ml) against the M. hyopneumoniae strains involved in this
study.
NCTC 10110
initial
NCTC 10110
final
Range
initial
Range
final
MIC50
initial
MIC50
final
MIC90
initial
MIC90
final
Fluoroquinolones
Enrofloxacin �0.039 0.078 �0.039–2.5 �0.039–5 �0.039 0.312 1.25 2.5
Marbofloxacin �0.039 0.156 �0.039–5 �0.039–10 �0.039 1.25 2.5 5
Tetracyclines
Oxytetracycline �0.25 4 �0.25–4 0.5–32 �0.25 4 2 16
Doxycycline �0.039 0.625 �0.039–0.625 0.078–2.5 0.078 0.625 0.312 2.5
Aminoglycoside
Gentamicin �0.25 1 �0.25–0.5 0.5–2 �0.25 1 0.5 2
Aminocyclitol
Spectinomycin 1 4 �0.25–4 1–8 2 4 2 4
Macrolides
Tylosin �0.25 0.5 �0.25–32 �0.25–64 0.25 0.5 �0.25 0.5
Tilmicosin 2 8 �0.25-�64 2->64 2 8 4 16
Tylvalosin �0.25 �0.25 �0.25–2 �0.25–8 �0.25 �0.25 �0.25 �0.25
Gamithromycin 1 4 �0.25–64 1->64 0.5 4 2 8
Tulathromycin 1 4 �0.25-�64 0.5->64 0.5 2 1 4
Lincosamide
Lincomycin �0.25 1 �0.25-�64 �0.25->64 �0.25 0.5 �0.25 1
Pleuromutilins
Tiamulin �0.039 0.156 �0.039–0.156 0.078–0.312 �0.039 0.156 0.078 0.156
Valnemulin �0.039 �0.039 �0.039 �0.039 �0.039 �0.039 �0.039 �0.039
Phenicol
Florfenicol 1 2 �0.125–2 1–4 1 2 2 4
https://doi.org/10.1371/journal.pone.0209030.t001
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synonymous substitutions were observed in genes associated with susceptibility to fluoroquin-
olones (gyrA, gyrB, parC and parE); however, only SNPs resulting in amino acid alterations
were further examined in the present study. None of the amino acid changes in the genes gyrB
and parE showed correlation with the defined MIC values. On the other hand, amino acid
changes in the gyrA gene (Gly81Ala, Ala83Val and Glu87Gly) and in the parC gene (Ser80Phe,
Ser80Tyr or Asp84Asn) correlated with decreased susceptibility of fluoroquinolones (S3
Table). Single alterations in the parC gene seem to have no crucial effect on fluoroquinolone
susceptibility when initial MIC values are examined. On the other hand, at least 12-fold con-
centration difference is observed in the final MIC values against strains, which contain a single
alteration in the parC gene. As opposed to the observed slight increase of MIC values of fluoro-
quinolones in association with the single substitution event in gene parC, double substitutions
in genes parC and gyrA correlated with final MIC values higher than 2 μg/ml in all cases, with
one exception (MycSu44). It is noteworthy, that the double substitutions in strain MycSu44
consisted of Ala83Val in gene gyrA and Asp84Asn in parC, while the rest of the strains showed
various amino acid substitution types in gene gyrA but only the change of serine at amino acid
Fig 1. Distribution of the minimal inhibitory concentrations of each tested antibiotic against the studied M. hyopneumoniae isolates. MIC50 and MIC90 values are
marked with black and white arrows, respectively.
https://doi.org/10.1371/journal.pone.0209030.g001
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position 80 in gene parC. The one outlier strain (MycSu17) against which 2.5–5 μg/ml initial
MIC values of fluoroquinolones were detected contained the double substitution combination
Ser80Phe (in parC gene) with Ala83Val (in gyrA gene). Correlation was described between
increased MIC values of macrolides and lincosamides against Mycoplasma species/ M. hyop-
neumoniae and SNPs in the 23S rRNA sequence [14,19]. A nucleotide substitution at the
position A2059G was found in the outlier strain (MycSu18) showing extremely decreased sus-
ceptibility to macrolides and lincosamides (S3 Table). The observed SNPs in the strains origi-
nating from the same herds were consistent with one exception: the strains originating from
Mezőtu´r (MycSu7; 8 and 41), which also clustered into completely different sequence types
according to earlier genotyping analysis [31] showed distinct susceptibility profiles and genetic
alterations correlating with antibiotic susceptibility.
Discussion
Antibiotic susceptibility testing of porcine mycoplasmas is not performed routinely, because it
is fastidious, time-consuming and requires special techniques and media [17]. Furthermore,
the lack of official standards makes the interpretation of the results difficult. The Clinical and
Laboratory Standards Institute (CLSI) has provided official breakpoints for certain antibiotics
but only for human pathogen mycoplasmas [35] and the procedures and media vary according
to each of the examined species [36].
Fluoroquinolones are potentially active antimicrobial agents against M. hyopneumoniae
through inhibition of the bacterial DNA gyrase and topoisomerase IV enzymes [19,22]. In the
present study, a broad range of MIC values was recorded with low MIC50 value of enrofloxa-
cin, similarly to previous results in other European publications in the last 20 years [11,13,34].
One of the examined strains (MycSu17) was inhibited by higher enrofloxacin concentration,
the MIC value against this strain exceeded the unofficial breakpoint determined by Hannan
et al. [11]. Similar observations have already been recorded with high MIC values in Thailand
(�2 μg/ml) and in Belgium (>1 μg/ml) [13,33], which forewarns the importance of suscepti-
bility testing before choosing antibiotics for treatment. Although MIC50 value of marbofloxa-
cin against the studied strains was mostly in accordance with recent data, MIC90 value against
the Hungarian isolates was higher than those against Belgian, Spanish and British strains (0.5–
1 μg/ml) [34].
No amino acid substitutions, correlating with increased MIC values, were observed in
the genes gyrB and parE, corroborating earlier publications [18]. Although single amino acid
substitutions in the parC gene (Ser80Phe, Ser80Tyr or Asp84Asn) showed correlation with
increased MIC values of fluoroquinolones in earlier publications [15,18,19], the degree of
increase seems to be negligible according to the initial MIC values detected in the present
study. However, definite increase of MIC values was detected when double substitutions in
parC and gyrA genes were described in the examined strains. The observed effect of the double
substitutions is in accordance with previous findings of Vicca et al. [18]. Various combinations
of amino acid changes were detected in the examined strains containing double substitutions
in the genes gyrA and parC, defining a unique combination in the outlier strain (MycSu17).
Moreover, new amino acid alterations (Glu87Gly and Gly81Ala) have been described in gyrA
gene of M. hyopenumoniae in the present study, which had been observed only in M. bovis and
M. gallisepticum before [23,24]. Factors influencing the degree of the decrease of susceptibility
to fluoroquinolones, such as the type of amino acid changes or mechanisms are yet to be dis-
covered. Although initial MIC values are advised to be taken into account in the interpretation
of the results of antibiotic susceptibility tests [37], correlations between the amino acid substi-
tutions and increased final MIC values were more defined in the current examinations and
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better supported previous observations, which highlights the usefulness of determining final
MIC values also.
The increasing susceptibility against fluoroquinolones is a notable problem, because these
agents are important antibiotics for human therapy [38]. To maximize efficacy and reduce
mutant selection in case of fluoroquinolones, the ratio of maximum serum concentration to
the MIC (Cmax/MIC ratio) of equal or higher than 10 was proposed [39]. Marbofloxacin
administered at 4 or 8 mg/kg intramuscularly resulted in 6.3 and 3.38 μg/ml Cmax in pigs [40]
respectively, resulting in maximum activity against strains with MICs of 0.625 and 0.3125 μg/
ml or lower in case of the two dosages, respectively.
Tetracyclines are frequently used to control M. hyopneumoniae infections, and they act by
binding to the decoding centre of the small ribosomal subunit of the bacterium [4,41]. Most of
the previous publications from Europe defined similar MIC50 and MIC90 values of oxytetracy-
cline [11,13,34]; but higher MIC50 and MIC90 values of doxycycline were described against
strains originating from Spain (1 μg/ml both) and Thailand (3.12 μg/ml and 6.25 μg/ml) than
against the Hungarian isolates. According to other publications supported also by our results,
tetracyclines are still active against M. hyopneumoniae despite of their long-standing usage in
human and veterinary medicine [32,33].
The aminoglycoside gentamicin seems to be an effective antimicrobial agent against
M. hyopneumoniae, as low MIC50 and MIC90 values were observed in the present study, simi-
larly to earlier data [13,32]. Although MIC range of the aminocyclitol spectinomycin was
broad similarly to the findings of a previous Spanish study, the MIC50 and MIC90 values were
higher in the present study compared to Spanish and Belgian MIC values [13,32].
Macrolides are among the most frequently used antibiotics in the swine industry to treat
M. hyopneumoniae infections [4]. Both 16-membered (tylosin, tilmicosin and tylvalosin) and
15-membered (tulathromycin and gamithromycin) macrolides were effective against the stud-
ied strains. However, the MIC value of tulathromycin against the type strain was three orders
of magnitude higher, than in the literature [34]. The reason of the discrepancy might be a dif-
ferent passage number of the type strain, or the different medium/antibiotic solution used dur-
ing the test. However, the MIC value of tulathromycin against the type strain did not exceed
16 μg/ml (a possible unofficial breakpoint according to other porcine respiratory pathogens
[42]) in either case. In the current study, a slight increase of MIC50 and MIC90 values of macro-
lides was described compared to the literature [34], and extremely high MIC values against an
outlier strain (MycSu18) was noted. According to the literature, nucleotide substitutions at the
bases 2057–2059 of the 23S rRNA sequence play an important role in acquired resistance to
macrolides [14,19,43]. Analysis of the 23S rRNA sequence of the strain MycSu18 revealed a
nucleotide substitution A2059G (E. coli numbering), which was also described in macrolide
and lincosamide resistant M. bovis strains before [24]. According to the habituation study of
Hannan et al. [12] and the high MIC values presented in this study, emergence of macrolide-
resistance could be a considerable problem, which was confirmed by earlier reported results
from Belgium [13], Thailand [33] and Spain [32].
Lincomycin is also active against M. hyopneumoniae, but extremely high MIC values appear
every now and then [13,32,33], like the outlier strain (MycSu18) in the present study. The rea-
son of the decreased susceptibility can be the cross-resistance with macrolides, as reported in
an earlier publication, which described decreasing susceptibility against tylosin and lincomy-
cin in strains originating from a lincomycin-treated herd [13]. The simultaneously appearing
change in susceptibility may lead back to the same mode of action of macrolides and lincosa-
mides, inhibiting bacterial protein synthesis on the 50S ribosomal subunit [44].
Pleuromutilins are important antibiotics to control M. hyopneumoniae infections through
inhibiting bacterial protein synthesis [45]. According to our results and other publications,
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tiamulin seems to be one of the most effective antimicrobial agents against M. hyopneumoniae
with low in vitro inhibitory concentrations [11–13,32–34]. Valnemulin is the most effective
antibiotic against all of the studied strains, which supported the earlier published observations
[12,32,34].
The chloramphenicol derivative florfenicol is an inhibitor of bacterial protein synthesis,
used exclusively for veterinary purposes [46]. The moderate distribution of the MIC range and
the relatively low MIC50 and MIC90 values of florfenicol, were similar to earlier observations
from different parts of Europe and Thailand [13,33,34], and they may indicate that this antibi-
otic is an effective agent against M. hyopneumoniae.
In vitro MIC values do not necessarily correlate with the effectiveness of the antimicrobials
in vivo and interpretation of the MIC distributions is difficult as Mycoplasma species with vet-
erinary relevance do not have official clinical breakpoints [34]. Furthermore, strains with dif-
ferent antibiotic susceptibility can coexist within a herd [33]. PK/PD (pharmacokinetic-
pharmacodynamic) analysis is an important tool to maximize in vivo antimicrobial activity
[47,48]. Most of our results were in accordance with other results of the European region, this
involves, that all the tested agents are most probably still suitable to control enzootic pneumo-
nia. Nonetheless the results of this study may help veterinarians to choose the proper antimi-
crobial agent against M. hyopneumoniae. Although the isolation of M. hyopneumoniae strains
is a time-consuming and fastidious process, the regularly accomplished antibiotic susceptibil-
ity testing of the swine herds should enable appropriate antibiotic usage during treatment. Fur-
thermore, the development of PCR-based susceptibility tests based on SNPs correlating with
changes in the MIC values, could improve diagnostics and treatment, similarly to antibiotic
susceptibility testing in M. bovis [24].
Conclusion
This study provided current and relevant information about the antibiotic susceptibility
profiles of M. hyopneumoniae strains circulating in Hungary and surrounding countries.
Low MIC values of all the tested antibiotics were described against most of the studied M.
hyopneumoniae strains, and the lowest MIC values were found in case of gentamicin, tylosin,
tylvalosin, lincomycin, tiamulin and valnemulin. In certain cases, high MIC values of fluoro-
quinolones (MycSu17) or macrolides and lincomycin (MycSu18) were observed. Single or
double amino acid substitutions in the genes gyrA (Gly81Ala, Ala83Val, Glu87Gly), parC
(Ser80Phe, Ser80Tyr, Asp84Asn) and a SNP in the 23S rRNA sequence (A2059G) were also
detected correlating with decreased antibiotic susceptibilities. Macrolides and fluoroquino-
lones are frequently used empirically as a first choice for the management of mycoplasmoses
in livestock in Europe. The regular testing of the sensitivity profile of M. hyopneumoniae, the
determination of herd specific MICs would promote the use of less critical antibacterials (e.g.:
florfenicol, tetracyclines, pleuromutilins), and might contribute to the preservation of the criti-
cally important antibiotics (macrolides and fluoroquinolones) both for veterinary and human
medicine.
Supporting information
S1 Table. Background data of M. hyopneumoniae strains and initial minimum inhibitory
concentration (MIC) values (μg/ml) of 15 antimicrobials against the strains used in the
study. Isolation data (Sample ID, Herd of origin and Date of isolation) and MIC values of
enrofloxacin (EFX), marbofloxacin (MFX), oxytetracycline (OTC), doxycycline (DX), genta-
micin (GTC), spectinomycin (SPC), tylosin (TYL), tilmicosin (TIL), tylvalosin (TVN), gami-
thromycin (GTM), tulathromycin (TTM), tiamulin (TIA), valnemulin (VAL), lincomycin
Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0209030 December 11, 2018 9 / 13
(LCM) and florfenicol (FFC) are presented. Abbreviations for herd of origin are: H-Hungary,
CZ-Czech Republic, SK-Slovakia.
(DOCX)
S2 Table. Background data of M. hyopneumoniae strains and final minimum inhibitory
concentration (MIC) values (μg/ml) of 15 antimicrobials against the strains used in the
study. Isolation data (Sample ID, Herd of origin and Date of isolation) and MIC values of
enrofloxacin (EFX), marbofloxacin (MFX), oxytetracycline (OTC), doxycycline (DX), genta-
micin (GTC), spectinomycin (SPC), tylosin (TYL), tilmicosin (TIL), tylvalosin (TVN), gami-
thromycin (GTM), tulathromycin (TTM), tiamulin (TIA), valnemulin (VAL), lincomycin
(LCM) and florfenicol (FFC) are presented. Abbreviations for herd of origin are: H-Hungary,
CZ-Czech Republic, SK-Slovakia.
(DOCX)
S3 Table. Initial and final minimum inhibitory concentration (MIC) ranges (μg/ml) of
fluoroquinolones, macrolides and lincomycin against the examined M. hyopneumoniae
isolates with the amino acid substitutions in the gyrA and parC genes and nucleotide sub-
stitutions in the 23S rRNA sequence.
(DOCX)
Author Contributions
Data curation: Miklo´s Gyuranecz.
Formal analysis: Kinga Ma´ria Sulyok.
Investigation: Orsolya Felde, Veronika Hrivna´k, Krisztia´n Kiss, Imre Biksi.
Methodology: Zsuzsa Kreizinger, Kinga Ma´ria Sulyok, Miklo´s Gyuranecz.
Project administration: Veronika Hrivna´k.
Resources: Miklo´s Gyuranecz.
Supervision: Miklo´s Gyuranecz.
Writing – original draft: Orsolya Felde, Zsuzsa Kreizinger.
Writing – review & editing: Kinga Ma´ria Sulyok, A´kos Jerzsele, Miklo´s Gyuranecz.
References
1. Artiushin S, Minion FC. Arbitrarily primed PCR analysis of Mycoplasma hyopneumoniae field isolates
demonstrates genetic heterogeneity. Int J Syst Evol Microbiol. 1996; 46:324–328.
2. Kobisch M, Friis NF. Swine mycoplasmoses. Rev Sci Tech. 1996; 15:1569–1605. PMID: 9190026
3. Maes D, Verdonck M, Deluyker H, de Kruif A. Enzootic pneumonia in pigs. Vet Q. 1996; 18:104–109.
https://doi.org/10.1080/01652176.1996.9694628 PMID: 8903144
4. Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F. Control of Mycoplasma hyopneumo-
niae infections in pigs. Vet Microbiol. 2008; 126:297–309. https://doi.org/10.1016/j.vetmic.2007.09.008
PMID: 17964089
5. Maes D, Sibila M, Kuhnert P, Segale´s J, Haesebrouck F, Pieters M. Update on Mycoplasma hyopneu-
moniae infections in pigs: Knowledge gaps for improved disease control. Transbound Emerg Dis. 2017;
https://doi.org/10.1111/tbed.12677 PMID: 28834294
6. Wyns H, Meyer E, Plessers E, Watteyn A, De Baere S, De Backer P, et al. Pharmacokinetics of gami-
thromycin after intravenous and subcutaneous administration in pigs. Res Vet Sci. 2014; 96:160–163.
https://doi.org/10.1016/j.rvsc.2013.11.012 PMID: 24331716
7. Pallare´s FJ, Lasa C, Roozen M, Ramis G. Use of tylvalosin in the control of porcine enzootic pneumo-
nia. Vet Rec Open. 2015;
Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0209030 December 11, 2018 10 / 13
8. El Garch F, de Jong A, Simjee S, Moyaert H, Klein U, Ludwig C, et al. Monitoring of antimicrobial sus-
ceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across Europe, 2009–
2012: VetPath results. Vet Microbiol. 2016; 194:11–22. https://doi.org/10.1016/j.vetmic.2016.04.009
PMID: 27102206
9. Thacker EL, Thacker BJ, Boettcher TB, Jayappa H. Comparison of antibody production, lymphocyte
stimulation, and protection induced by four commercial Mycoplasma hyopneumoniae bacterins. Swine
Health Prod. 1998; 6:107–112.
10. McCormack WM. Susceptibility of mycoplasmas to antimicrobial agents: Clinical implications. Clin
Infect Dis. 1993; 17:200–201.
11. Hannan PCT, Windsor GD, De Jong A, Schmeer N, Stegemann M. Comparative susceptibilities of vari-
ous animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob Agents Chemother. 1997;
41:2037–2040. PMID: 9303412
12. Hannan PCT, Windsor HM, Ripley PH. In vitro susceptibilities of recent field isolates of Mycoplasma
hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and
the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae.
Res Vet Sci. 1997; 63:157–160. PMID: 9429250
13. Vicca J, Stakenborg T, Maes D, Butaye P, Peeters J, de Kruif A, et al. In vitro susceptibilities of Myco-
plasma hyopneumoniae field isolates. Antimicrob Agents Chemother. 2004; 48:4470–4472. https://doi.
org/10.1128/AAC.48.11.4470-4472.2004 PMID: 15504886
14. Stakenborg T, Vicca J, Butaye P, Maes D, Minion FC, Peeters J, et al. Characterization of in vivo
acquired resistance of Mycoplasma hyopneumoniae to macrolides and lincosamides. Microb Drug
Resist. 2005; 11:290–294. https://doi.org/10.1089/mdr.2005.11.290 PMID: 16201934
15. Le Carrou J, Laurentie M, Kobisch M, Gautier-Bouchardon AV. Persistence of Mycoplasma hyopneu-
moniae in experimentally infected pigs after marbofloxacin treatment and detection of mutations in the
parC gene. Antimicrob Agents Chemother. 2006; 50:1959–1966. https://doi.org/10.1128/AAC.01527-
05 PMID: 16723552
16. Yamamoto K, Koshimizu K, Ogata M. In vitro susceptibility of Mycoplasma hyopneumoniae to antibiot-
ics. Japanese J Vet Sci. 1986; 48:1–5.
17. Hannan PCT. Guidelines and recommendations for antimicrobial minimum inhibitory concentration
(MIC) testing against veterinary mycoplasma species. Vet Res. 2000; 31:373–395. https://doi.org/10.
1051/vetres:2000100 PMID: 10958240
18. Vicca J, Maes D, Stakenborg T, Butaye P, Minion F, Peeters J, et al. Resistance mechanism against flu-
oroquinolones in Mycoplasma hyopneumoniae field isolates. Microb Drug Resist. 2007; 13:166–170.
https://doi.org/10.1089/mdr.2007.716 PMID: 17949302
19. Gautier-Bouchardon AV. Antimicrobial resistance in Mycoplasma spp. Microbiol Spectr. 2018; https://
doi.org/10.1128/microbiolspec.ARBA-0030-2018 PMID: 30003864
20. Felde O, Kiss K, Biksi I, Jerzsele A´ , Gyuranecz M. A serte´sek Mycoplasma hyopneumoniae okozta
tu¨dő gyullada´sa. (Pneumonia of pigs caused by Mycoplasma hyopneumoniae) Magy A´ llatorvosok
Lapja. 2018; 140:337–348.
21. European Centre for Disease Prevention and Control, European Food Safety Authority, and European
Medicines Agency, ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of
antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-pro-
ducing animals. EFSA J. 2015;
22. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis.
2000; 31(Supplement_2):S24–28.
23. Reinhardt AK, Kempf I, Kobisch M, Gautier-Bouchardon AV. Fluoroquinolone resistance in Myco-
plasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topo-
isomerases on resistance level. J Antimicrob Chemother. 2002; 50:589–592. https://doi.org/10.1093/
jac/dkf158 PMID: 12356806
24. Sulyok KM, Kreizinger Z, Wehmann E, Lysnyansky I, Ba´nyai K, Marton S, et al. Mutations associated
with decreased susceptibility to seven antimicrobial families in field and laboratory-derived Mycoplasma
bovis strains. Antimicrob Agents Chemother. 2017; https://doi.org/10.1128/AAC.01983-16 PMID:
27895010
25. Vester B, Douthwaite S. Macrolide Resistance conferred by base substitutions in 23S rRNA Antimicrob
Agents Chemother. 2001; 45:1–12. https://doi.org/10.1128/AAC.45.1.1-12.2001 PMID: 11120937
26. Friis NF. Some recommendations concerning primary isolation of Mycoplasma suipneumoniae and
Mycoplasma flocculare a survey. Nord Vet Med. 1975; 27:337–339. PMID: 1098011
27. Etheridge JR, Cottew GS, Lloyd LC. Isolation of Mycoplasma hyopneumoniae from lesions in experi-
mentally infected pigs. Aust Vet J. 1979; 55:356–359. PMID: 533486
Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0209030 December 11, 2018 11 / 13
28. Mattsson JG, Bergstro¨m K, Wallgren P, Johansson KE. Detection of Mycoplasma hyopneumoniae in
nose swabs from pigs by in vitro amplification of the 16S rRNA gene. J Clin Microbiol. 1995; 33:893–
897. PMID: 7540629
29. Lauermann LH, Chilina AR, Closser JA, Johansen D. Avian Mycoplasma identification using polymer-
ase chain reaction amplicon and restriction fragment length polymorphism analysis. Avian Dis. 1995;
39:804–811. PMID: 8719214
30. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious Basic : An inte-
grated and extendable desktop software platform for the organization and analysis of sequence data.
Bioinformatics. 2012; 28:1647–1649. https://doi.org/10.1093/bioinformatics/bts199 PMID: 22543367
31. Felde O, Kreizinger Z, Sulyok KM, Marton S, Ba´nyai K, Korbuly K, et al. Genotyping Mycoplasma hyop-
neumoniae isolates based on multi-locus sequence typing, multiple-locus variable-number tandem
repeat analysis and analysing gene p146. Vet Microbiol. 2018; 222:85–90. https://doi.org/10.1016/j.
vetmic.2018.07.004 PMID: 30080678
32. Tavı´o MM, Poveda C, Assunc¸ão P, Ramı´rez AS, Poveda JB. In vitro activity of tylvalosin against Span-
ish field strains of Mycoplasma hyopneumoniae. Vet Rec. 2014; https://doi.org/10.1136/vr.102458
PMID: 25185108
33. Thongkamkoon P, Narongsak W, Kobayashi H, Pathanasophon P, Kishima M, Yamamoto K. In vitro
susceptibility of Mycoplasma hyopneumoniae field isolates and occurrence of fluoroquinolone, macro-
lides and lincomycin resistance. J Vet Med Sci. 2013; 75:1067–1670. PMID: 23503167
34. Klein U, de Jong A, Moyaert H, El Garch F, Leon R, Richard-Mazet A, et al. Antimicrobial susceptibility
monitoring of Mycoplasma hyopneumoniae and Mycoplasma bovis isolated in Europe. Vet Microbiol.
2017; 204:188–193. https://doi.org/10.1016/j.vetmic.2017.04.012 PMID: 28532800
35. Wayne P. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility
testing for human mycoplasmas; Approved guideline. CLSI document M43-A. 2011.
36. Waites KB, Duffy LB, Be´be´ar CM, Matlow A, Talkington DF, Kenny GE, et al. Standardized methods
and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumo-
niae, Mycoplasma hominis, and Ureaplasma urealyticum. J Clin Microbiol. 2012; 50:3542–3547. https://
doi.org/10.1128/JCM.01439-12 PMID: 22915608
37. Kreizinger Z, Gro´zner D, Sulyok KM, Nilsson K, Hrivna´k V, Benčina D, et al. Antibiotic susceptibility pro-
files of Mycoplasma synoviae strains originating from Central and Eastern Europe. BMC Vet Res. 2017;
https://doi.org/10.1186/s12917-017-1266-2 PMID: 29149886
38. Collignon P, Powers JH, Chiller TM, Aidara-Kane A, Aarestrup FM. World Health Organization ranking
of antimicrobials according to their importance in human medicine: A critical step for developing risk
management strategies for the use of antimicrobials in food production animals. Clin Infect Dis. 2009;
49:132–141. https://doi.org/10.1086/599374 PMID: 19489713
39. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. In: Pharma-
cotherapy: the journal of human pharmacology and drug therapy. 2001. 233S–252S.
40. Schneider M, Paulin A, Dron F, Woehrle´ F. Pharmacokinetics of marbofloxacin in pigs after intravenous
and intramuscular administration of a single dose of 8 mg/kg: dose proportionality, influence of the age
of the animals and urinary elimination. Vet Pharmacol Ther. 2014; 37:523–530. https://doi.org/10.1111/
jvp.12125 PMID: 24666477
41. Nguyen F, Starosta AL, Arenz S, Sohmen D, Do¨nho¨fer A, Wilson DN. Tetracycline antibiotics and resis-
tance mechanisms. Biol Chem. 2014; 395:559–575. https://doi.org/10.1515/hsz-2013-0292 PMID:
24497223
42. Godinho KS. Susceptibility testing of tulathromycin: Interpretative breakpoints and susceptibility of field
isolates. Vet Microbiol. 2008; 129:426–432. https://doi.org/10.1016/j.vetmic.2007.11.033 PMID:
18187275
43. Hansen JL, Ippolito JA, Ban N, Nissen P, Moore PB, Steitz TA. The structures of four macrolide antibiot-
ics bound to the large ribosomal subunit. Mol Cell. 2002; 10:117–128. PMID: 12150912
44. Weisblum B. Insights into erythromycin action from studies of its activity as inducer of resistance. Anti-
microb Agents Chemother. 1995; 39:797–805. PMID: 7785974
45. Poulsen SM, Karlsson M, Johansson LB, Vester B. The pleuromutilin drugs tiamulin and valnemulin
bind to the RNA at the peptidyl transferase centre on the ribosome. Mol Microbiol. 2001; 41:1091–1099.
PMID: 11555289
46. Priebe S, Schwarz S. In vitro activities of florfenicol against bovine and porcine respiratory tract patho-
gens. Antimicrob Agents Chemother. 2003; 47:2703–2705. https://doi.org/10.1128/AAC.47.8.2703-
2705.2003 PMID: 12878547
Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0209030 December 11, 2018 12 / 13
47. Ahmad I, Huang L, Hao H, Sanders P, Yuan Z. Application of PK / PD modeling in veterinary field :
Dose optimization and drug resistance prediction. Biomed Res Int. 2016; https://doi.org/10.1155/2016/
5465678 PMID: 26989688
48. Somogyi Z, Karancsi Z, Jerzsele A´ . Farmakokinetika/farmakodina´mia (PK/PD) megko¨zelı´te´s az a´llat-
gyo´gya´szatban: Irodalmi o¨sszefoglalo´. (Pharmacokinetics/pharmacodynamics approach in the veteri-
nary medicine: Literature review) Magy A´ llatorvosok Lapja. 2018; 14:37–46.
Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0209030 December 11, 2018 13 / 13
